News
Investment firms in Boston and New York could see the biggest gains from the sale of a Raleigh drugmaker. Raleigh pharma ...
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...
6h
MONTCO Today on MSNWSJ: Merck Makes $10 Billion Move as Keytruda Patent Expiration NearsMerck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...
The pharmaceutical industry is staring down a major patent cliff, with key drugs from Merck (MRK), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ) set to lose exclusivity by 2030. Yahoo ...
23h
Zacks Investment Research on MSNMerck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...
Pharmaceutical titan Merck & Co. Inc. has announced a landmark $10 billion acquisition of Verona Pharma plc, underscoring its ...
U.S. appetite for U.K. companies is only intestifying in 2025; here, Law.com charts some of the highest profile deals in H1, ...
For the third time in four years, CNBC has ranked North Carolina as “America’s Top State for Business” in 2025.
Bank of America Securities analyst Jason Gerberry reiterated a Sell rating on ProKidney yesterday and set a price target of $1.00. The company’s shares opened today at $4.82. Take advantage of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results